Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4B | O94953 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | PTAFR | P25105 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411578 | 1.00 | KDM4B (0.46) | KDM4BDYRK1ACLK1CLK2CLK4 | |
| SCHEMBL21045362 | 0.93 | DYRK1A (0.45) | KDM4BDYRK1ACLK1CLK2CLK4 | |
| SCHEMBL21045208 | 0.84 | PTAFR (0.52) | PTAFRKDM4ECTSVCTSLCTSS | |
| SCHEMBL29411529 | 0.84 | PTAFR (0.52) | PTAFRKDM4ECTSVCTSLCTSS | |
| SCHEMBL21045206 | 0.84 | PTAFR (0.46) | PTAFRPOLBKDM4ECTSVCTSL | |
| SCHEMBL29411369 | 0.84 | PTAFR (0.46) | PTAFRPOLBKDM4ECTSVCTSL | |
| SCHEMBL29411479 | 0.83 | PTAFR (0.40) | DYRK1ACLK2PTAFRCTSVCTSL | |
| SCHEMBL21045187 | 0.83 | PTAFR (0.40) | DYRK1ACLK2PTAFRCTSVCTSL | |
| SCHEMBL21045250 | 0.82 | PTAFR (0.52) | KDM4BPTAFRKDM4E | |
| SCHEMBL29411440 | 0.82 | PTAFR (0.52) | KDM4BPTAFRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
| US-11040945-B2 | Tubulin inhibitors | LIN BIOSCIENCE PTY LTD. | 2021-06-22 | — | — | US | disclosed |
| US-11040945-B2 | Tubulin inhibitors | LIN BIOSCIENCE PTY LTD. | 2021-06-22 | — | — | US | disclosed |
| WO-2019113242-A1 | TUBULIN INHIBITORS | Lin BioScience, LLC (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190169127-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2019-06-06 | — | — | US | disclosed |
| US-20190169127-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | KDM4B 3964/4885DYRK1A 2699/4885CLK1 872/4885 |
| US-11040945-B2 | Tubulin inhibitors | TUBB3, TUBB1, TUBB | KDM4B 3964/4885DYRK1A 2699/4885CLK1 872/4885 |
| US-20190169127-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | KDM4B 3964/4885DYRK1A 2699/4885CLK1 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.